Longeveron LLC

Yahoo Finance • yesterday

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Thepatent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dila... Full story

Yahoo Finance • 2 days ago

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to placebo across multiple k... Full story

Yahoo Finance • 6 days ago

MODD, LAB, HOWL, COGT, LGVN, ABCL Lead Biotech After-Hours Rally - Nov 26

(RTTNews) - Several biotech and life sciences companies posted notable gains in after-hours trading on Wednesday, November 26, reflecting investor interest despite a relatively quiet news cycle. Modular Medical, Inc. (MODD) shares surged... Full story

Yahoo Finance • 14 days ago

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that i... Full story

Yahoo Finance • 21 days ago

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Thepatent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved treatments for aging-related frailty,... Full story

Yahoo Finance • last month

Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that... Full story

Yahoo Finance • last month

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHSFull enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as... Full story

Yahoo Finance • 2 months ago

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that... Full story

Yahoo Finance • 2 months ago

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that... Full story

Yahoo Finance • 2 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 2 months ago

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsCle... Full story

Yahoo Finance • 3 months ago

Longeveron appoints interim CEO

* Longeveron (NASDAQ:LGVN [https://seekingalpha.com/symbol/LGVN]) appointed Than Powell as interim chief executive officer, effective immediately. * Powell replaces Wa’el Hashad. * Company founder and chief science officer Joshua Har... Full story

Yahoo Finance • 3 months ago

Longeveron® Announces Key Leadership Updates

Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa’el Hashad to step down as CEO and Bo... Full story

Yahoo Finance • 3 months ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions... Full story

Yahoo Finance • 4 months ago

These stocks have an unusual volume in today's session

These stocks have an unusual volume in today's session [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT ADD [https://www.chartmill.com/stock/quote/ADD/profile] -9.78% The trading volume of COLOR STAR TECHNO... Full story

Yahoo Finance • 4 months ago

Longeveron reports Q2 results

* Longeveron press release [https://seekingalpha.com/pr/20200156-longeveron-announces-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:LGVN [https://seekingalpha.com/symbol/LGVN]): Q2 GAAP EPS of -$0.33 beats b... Full story

Yahoo Finance • 4 months ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II top-line trial results are antici... Full story

Yahoo Finance • 4 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chro... Full story

Yahoo Finance • 4 months ago

Top stock movements in today's session.

Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT MRM... Full story

Yahoo Finance • 4 months ago

Longeveron Announces Up To $17.5 Million Public Offering

MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chro... Full story